Public Assessment Report

Decentralised Procedure

Vastacop XL 80mg Prolonged Release Tablets

Fluvastatin sodium

UK/H/1108/01/DC

UK licence no: PL 20254/0007

Applicant: Orifarm Generics A/S
LAY SUMMARY

The MHRA granted Orifarm Generics A/S Marketing Authorisation (licence) for the medicinal product Vastacop XL 80mg prolonged release tablets (PL 20254/0007) on 13th November 2008. This is a prescription only medicine (POM).

The active ingredient in your tablets is fluvastatin. It works by reducing the amount of cholesterol your body makes. Cholesterol is a type of fat, which is vital to the normal functioning of the body. If levels of cholesterol in the blood are too high, it can be deposited on the walls of the arteries. There it builds up to form plaques that can eventually block the blood vessel.

No new or unexpected safety concerns arose from this application and it was therefore judged that the benefits of taking this medicine outweigh the risks, hence Marketing Authorisation has been granted.
TABLE OF CONTENTS

Module 1: Information about initial procedure Page 4

Module 2: Summary of Product Characteristics Page 5

Module 3: Product Information Leaflet Page 13

Module 4: Labelling Page 15

Module 5: Scientific Discussion Page 16

1 Introduction
2 Quality aspects
3 Non-clinical aspects
4 Clinical aspects
5 Overall conclusions

Module 6 Steps taken after initial procedure
Module 1

<table>
<thead>
<tr>
<th><strong>Product Name</strong></th>
<th>Vastacop XL 80mg prolonged release tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Type of Application</strong></td>
<td>Generic, Article 10.1</td>
</tr>
<tr>
<td><strong>Active Substance</strong></td>
<td>Fluvastatin sodium</td>
</tr>
<tr>
<td><strong>Form</strong></td>
<td>Prolonged release tablets</td>
</tr>
<tr>
<td><strong>Strength</strong></td>
<td>80mg</td>
</tr>
<tr>
<td><strong>MA Holder</strong></td>
<td>Orifarm Generics A/S</td>
</tr>
<tr>
<td><strong>RMS</strong></td>
<td>UK</td>
</tr>
<tr>
<td><strong>CMS</strong></td>
<td>DE, FI, NO and SE</td>
</tr>
<tr>
<td><strong>Procedure Number</strong></td>
<td>UK/H/1108/01/DC</td>
</tr>
<tr>
<td><strong>Timetable</strong></td>
<td>Day 210–21st September 2008</td>
</tr>
</tbody>
</table>
Module 2

SUMMARY OF PRODUCT CHARACTERISTICS

1 NAME OF THE MEDICINAL PRODUCT
Vastacop XL 80mg prolonged release tablets

2 QUALITATIVE AND QUANTITATIVE COMPOSITION
84.2mg fluvastatin sodium corresponding to 80mg fluvastatin.
For a full list of excipients, see section 6.1

3 PHARMACEUTICAL FORM
Prolonged release tablet.
Vastacop XL tablets are dark yellow, round, biconvex tablets. 10.1 ± 0.1 mm in diameter and 4.0mm ± 0.2 mm in thickness

4 CLINICAL PARTICULARS

4.1 Therapeutic indications
Vastacop XL is indicated as an adjunct to diet for the reduction of elevated total cholesterol (total-C) and low-density lipoprotein cholesterol (LDL-C) levels, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate in patients with primary hypercholesterolaemia and mixed dyslipidaemia (Fredrickson Types IIa and IIb).
Vastacop XL is also indicated in patients with coronary heart disease for the secondary prevention of coronary events after percutaneous coronary intervention, see Section 5.1.

4.2 Posology and method of administration
Prior to initiating Vastacop XL, secondary causes of hypercholesterolaemia should be excluded, and the patient placed on a standard cholesterol-lowering diet. Dietary therapy should be continued during treatment.
• Dose recommendations for lipid lowering effect
The recommended starting dose is 40 mg (1 capsule Fluvastatin 40 mg) once daily although a dose of 20 mg fluvastatin (1 capsule Fluvastatin 20 mg) once daily may be adequate in mild cases. Most patients will require a dose of 20 mg to 40 mg once daily but the dose may be increased to 80 mg (1 tablet Vastacop XL) once daily, individualised according to baseline LDL-C levels and the recommended goal of therapy to be accomplished. The maximum recommended daily dose is 80 mg once daily.
Vastacop XL can be administered as a single dose at any time of the day with or without food and must be swallowed whole with a glass of water. The maximum lipid-lowering effect with a given dose of the drug is achieved within 4 weeks. Doses should be adjusted according to the patient's response and dose adjustment made at intervals of 4 weeks or more. The therapeutic effect of Vastacop XL is maintained with prolonged administration.
Vastacop XL is efficacious in monotherapy or in combination with bile acid sequestrants. When Vastacop XL is used in combination with cholestyramine or other resins, it should be administered at least 4 hours after the resin to avoid a significant interaction due to binding of the drug to the resin. Minimal data exist to support the efficacy and safety of Vastacop XL in combination with nicotinic acid or fibrates (see Section 4.5 Interactions with other medicaments and other forms of interaction).
• Dose recommendations for the secondary prevention of coronary events after percutaneous coronary intervention
In patients with coronary heart disease after percutaneous coronary intervention, the dose is 80 mg daily.
Patients with impaired kidney function
Fluvastatin is cleared by the liver, with less than 6% of the administered dose excreted into the urine. The pharmacokinetics of fluvastatin remains unchanged in patients with mild to severe renal insufficiency (Creatinine Clearance < 60 mL/min). No dose adjustments are therefore necessary in these patients.
However, since fluvastatin has not been studied at doses greater than 40 mg in patients with severe renal impairment, caution should be exercised when treating such patients at higher doses.
Patients with impaired liver function
Vastacop XL is contraindicated in patients with active liver disease, or unexplained, persistent elevations in serum transaminases (see 4.3 Contraindications and 4.4 Special warnings and special precautions for use).

Use in the elderly
There is no evidence of reduced tolerability or altered dosage requirements in elderly patients.

Use in children and adolescents
Fluvastatin is not recommended for use in children and adolescents under the age of 18 years due to insufficient data on safety and efficacy (see section 4.4)

4.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients.
Patients with active liver disease, hepatic impairment, or unexplained, persistent elevations in serum transaminases (see section 4.2 and 4.8).
Patients with myopathy.
During pregnancy and lactation (see section 4.6).

4.4 Special warnings and precautions for use
HMG-CoA reductase inhibitors, including Vastacop XL are unlikely to be of benefit in patients with rare homozygous familial hypercholesterolaemia.
As with other lipid-lowering drugs, it is recommended that liver function tests be performed before the initiation of treatment and at 12 weeks following initiation of treatment or elevation in dose and periodically thereafter in all patients. Should an increase in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) exceed 3 times the upper limit of normal and persist, therapy should be discontinued. In very rare cases, possibly drug-related hepatitis was observed that resolved upon discontinuation of treatment.
Caution should be exercised when Vastacop XL is administered to patients with a history of liver disease or heavy alcohol ingestion.
Since fluvastatin is eliminated primarily via the biliary route and is subject to significant pre-systemic metabolism, the potential exists for drug accumulation in patients with hepatic insufficiency. Caution should be exercised when fluvastatin is administered in patients with hypothyroidism.
Fluvastatin is not recommended for use in children and adolescents under the age of 18 years due to insufficient data on safety and efficacy (see section 4.2).

Skeletal muscle
With Vastacop XL, myopathy has rarely been reported, whereas myositis and rhabdomyolysis have been reported very rarely. In patients with unexplained diffuse myalgias, muscle tenderness or muscle weakness, and/or marked elevation of creatine kinase (CK) values, myopathy, myositis or rhabdomyolysis have to be considered. Patients should therefore be advised to report promptly unexplained muscle pain, muscle tenderness or muscle weakness, particularly if accompanied by malaise or fever.

Interstitial lung disease
Exceptional cases of interstitial lung disease have been reported with some statins, especially with long term therapy (see section 4.8). Presenting features can include dyspnoea, non-productive cough and deterioration in general health (fatigue, weight loss and fever). If it is suspected a patient has developed interstitial lung disease, statin therapy should be discontinued.

Creatine kinase measurement
There is no current evidence to require routine monitoring of plasma total creatine kinase or other muscle enzyme levels in asymptomatic patients on statins. If creatine kinase has to be measured it should not be done following strenuous exercise or in the presence of any plausible alternative cause of CK-increase as this makes the value interpretation difficult.

Before the treatment
As with all other statins physicians should prescribe fluvastatin with caution in patients with pre-disposing factors for rhabdomyolysis and its complications. A creatine kinase level should be measured before starting fluvastatin treatment in the following situations:
• Renal impairment
• Hypothyroidism
• Personal or familial history of hereditary muscular disorders
• Previous history of muscular toxicity with a statin or fibrate
• Alcohol abuse
• In elderly (age> 70 years), the necessity of such measurement should be considered, according to the presence of other predisposing factors for rhabdomyolysis.
In such situations, the risk of treatment should be considered in relation to the possible benefit and clinical monitoring is recommended. If CK-levels are significantly elevated at baseline > 5xULN),
levels should be re-measured within 5 to 7 days later to confirm the results. If CK-levels are still significantly elevated (> 5xULN) at baseline, treatment should not be started.

**Whilst on treatment**

If muscular symptoms like pain, weakness or cramps occur in patients receiving fluvastatin, their CK-levels should be measured. Treatment should be stopped, if these levels are found to be significantly elevated (> 5xULN).

If muscular symptoms are severe and cause daily discomfort, even if CK-levels are elevated to ≤5 x ULN, treatment discontinuation should be considered.

Should the symptoms resolve and CK-levels return to normal, then re-introduction of fluvastatin or another statin may be considered at the lowest dose and under close monitoring.

The risk of myopathy is known to be increased in patients receiving immunosuppressive drugs (including cyclosporin), fibrates, nicotinic acid or erythromycin together with other HMG-CoA reductase inhibitors. Minimal data exist to support the efficacy or safety of Vastacop XL in combination with nicotinic acid, its derivatives, fibrates or cyclosporin. Vastacop XL should be used with caution in patients receiving such concomitant medication (see Section 4.5).

### 4.5 Interaction with other medicinal products and other forms of interaction

Fluvastatin is substantially metabolised by cytochrome P450 (CYP2C9). Other substrates or inhibitors of CYP2C9 administered concomitantly may therefore potentially result in increased plasma levels of fluvastatin, with a consequent increased risk of myopathy (see section 4.4).

**Food interactions**

Mean AUC and Cmax were increased by 49% and 45% respectively and tmax prolonged when fluvastatin (Vastacop XL) was taken with food, compared to fasting state. However, no clinically obvious differences in the lipid lowering effects and safety are anticipated when fluvastatin is taken with or without food.

**Drug interactions**

Effects of other drugs on fluvastatin:

- **Ciclosporin** - In an interaction study concomitant administration of fluvastatin (up to 40mg/day) and ciclosporin resulted in an increase in the bioavailability of fluvastatin by a factor of 1.9. The results from another study wherein Vastacop XL (80 mg fluvastatin) was administered to renal transplant patients who were on stable ciclosporin regimen showed that fluvastatin exposure (AUC) and maximum concentration (Cmax) were increased by 2 fold compared to historical data in healthy subjects. The combination of fluvastatin and ciclosporin should be used with caution due to the potential for an increased risk of myopathy and/or rhabdomyolysis (see section 4.4 Special warnings and special precautions for use).

  - **Fibrac acid derivatives (fibrates) and nicotinic acid:**
    - **Bezafibrate** - An interaction study between 20mg o.d. fluvastatin and 200mg t.d.s. bezafibrate showed that mean AUC and Cmax values of fluvastatin were increased on average by about 50-60%. No effect was seen on bezafibrate pharmacokinetics. This combination should be used with caution, however, due to the increased risk of developing myopathy and/or rhabdomyolysis when HMG-CoA reductase inhibitors including fluvastatin have been combined with fibrates. Any patient complaining of myalgia should be carefully evaluated.
    - **Gemfibrozil** - In an interaction study the concomitant administration of fluvastatin and gemfibrozil had no effect on the pharmacokinetics of either drug. The combination should be used with caution however, due to reports of an increased risk of myopathy and/or rhabdomyolysis when other HMG-CoA reductase inhibitors have been combined with fibrates.
    - **Ciprofibrate** - Concomitant administration of fluvastatin and ciprofibrate has no effect on the bioavailability of fluvastatin. However, the combination should be used with caution due to reports of an increased risk of myopathy and/or rhabdomyolysis when ciprofibrate is used in combination with other HMG-CoA reductase inhibitors.
    - **Nicotinic acid** - Concomitant administration of fluvastatin and nicotinic acid has no effect on the bioavailability of fluvastatin. However, the combination should be used with caution due to reports of an increased risk of myopathy and/or rhabdomyolysis when nicotinic acid is used in combination with other HMG-CoA reductase inhibitors.

  - **Erythromycin** - There are reports of an increased risk of myopathy and/or rhabdomyolysis when other HMG-CoA reductase inhibitors have been combined with erythromycin. The results from an interaction study with a small number of healthy volunteers suggested that erythromycin and fluvastatin were not metabolised by the same isoenzyme, however caution should be exercised when these two drugs are given in combination in view of the interaction seen with other HMG-CoA reductase inhibitors.

  - **Fluconazole** - Administration of fluvastatin to healthy volunteers pre-treated with fluconazole (CYP 2C9 inhibitor) resulted in an increase in the exposure (AUC) and mean peak concentration (Cmax) of
fluvastatin by about 84% and 44% respectively. Caution should be exercised when fluvastatin is administered concomitantly with fluconazole.

Itraconazole – No interactions have been seen with itraconazole. Nevertheless patients should be closely monitored.

Antipyrine - Administration of fluvastatin does not influence the metabolism and excretion of antipyrine. As antipyrine is a model for drugs metabolised by the microsomal hepatic enzyme systems, interactions with other drugs metabolised by these systems are not expected.

Propranolol - Concomitant administration of fluvastatin with propranolol has no effect on the bioavailability of fluvastatin.

Bile-acid sequestering agents - Administration of fluvastatin 4 hours after cholestyramine results in a clinically significant additive effect compared with that achieved with either drug alone. Vastacop XL should be administered at least 4 hours after the resin (e.g. cholestyramine) to avoid a significant interaction due to drug binding to the resin.

Digoxin - Concomitant administration of fluvastatin with digoxin has no effect on digoxin plasma concentrations.

Amlodipine - No clinically significant pharmacokinetic interactions occur when fluvastatin is concomitantly administered with amlodipine.

Cimetidine/ranitidine/omeprazole - Concomitant administration of fluvastatin with cimetidine, ranitidine or omeprazole results in an increase in the bioavailability of fluvastatin, which, however, is of no clinical relevance.

Rifampicin - Administration of fluvastatin to subjects pre-treated with rifampicin resulted in a reduction of the bioavailability of fluvastatin by about 50%. Although at present there is no clinical evidence that fluvastatin efficacy in lowering lipid levels is altered, for patients undertaking long-term rifampicin therapy (e.g. treatment of tuberculosis), appropriate adjustment of fluvastatin dosage may be warranted to ensure a satisfactory reduction in lipid levels.

Phenytoin – In an interaction study concomitant administration of fluvastatin and phenytoin resulted in an increase of fluvastatin mean AUC and Cmax values by 40% and 27% respectively. This combination should be used with caution due to the increased risk of developing myopathy and/or rhabdomyolysis.

Effects of fluvastatin on other drugs:

Ciclosporin - Vastacop XL had no effect on ciclosporin bioavailability when co-administered (see also Effects of other drugs on fluvastatin).

Phenytoin - Co-administration of fluvastatin (40 mg b.i.d. for 5 days) increased the mean Cmax of phenytoin by 5% whereas the mean AUC was increased by 22%. Patients on phenytoin should be carefully monitored when fluvastatin therapy is initiated or when the dose is increased.

Warfarin and other coumarin derivatives - Co-administration of fluvastatin with warfarin may commonly cause significant increases in prothrombin time. This has resulted very rarely in serious haemorrhage. It is recommended that prothrombin times are monitored when fluvastatin therapy is initiated, discontinued or the dosage changed in patients receiving warfarin or other coumarin derivative.

Glibenclamide - An interaction study between fluvastatin 40mg b.i.d. and glibenclamide was done in diabetic patients stabilised on 5-20mg of glibenclamide. The AUC for glibenclamide increased on average by 1.7 times (range: 0.9 – 3.5), Cmax increased on average by 1.6 times (range: 0.9 -3.0) and the mean t1/2 of glibenclamide increased from 8.5 to 18.8 hours when taken with fluvastatin. In this study there were no significant changes in glucose levels but in view of the increases seen in glibenclamide levels there remains a potential for serious hypoglycaemia and this combination should be avoided whenever possible.

Other concomitant therapy - In clinical studies in which fluvastatin was used concomitantly with angiotensin converting enzyme (ACE) inhibitors, beta-blockers, calcium channel blockers, salicylic acid, H2-blockers and non-steroidal anti-inflammatory drugs (NSAIDs), no clinically significant adverse interactions occurred.

Colchicines

Isolated cases of myopathy have been reported during post-marketing experience with concomitant administration of fluvastatin and colchicine. No information is available on the pharmacokinetic interaction between fluvastatin and colchicine. However, myotoxicity, including muscle pain and weakness and rhabdomyolysis, have been reported anecdotally with concomitant administration of colchicine.

4.6 Pregnancy and lactation

Animal studies have indicated that fluvastatin is devoid of embryotoxic and teratogenic potential. However, since HMG-CoA reductase inhibitors decrease the synthesis of cholesterol and possibly of other biologically active substances derived from cholesterol, they may cause fetal harm when administered to pregnant women. Therefore, Fluvastatin is suspected to cause serious birth defects
when administered during pregnancy. Therefore HMG-CoA reductase inhibitors are contraindicated during pregnancy and in women of childbearing potential not taking adequate contraceptive precautions. If a patient becomes pregnant while taking this class of drug, therapy should be discontinued. As small amounts of fluvastatin have been found in rat milk, Vastacop XL is contraindicated in nursing mothers (see section 4.3).

4.7 Effects on ability to drive and use machines
No studies of the effect of the ability to drive and use machines have been performed. Dizziness and fatigue have been reported as side effects. Therefore caution is recommended when driving and using machines.

4.8 Undesirable effects
Adverse reactions (Table 1) are ranked under heading of frequency, the most frequent first, using the following convention: very common (≥ 1/10); common (≥ 1/100, < 1/10); uncommon (≥ 1/1,000, < 1/100); rare (≥ 1/10,000, < 1/1,000) very rare (< 1/10,000), including isolated reports. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. The most commonly reported adverse drug reactions are minor gastrointestinal symptoms, insomnia and headache.

<table>
<thead>
<tr>
<th>System Organ Classes</th>
<th>Very common ≥1/10</th>
<th>Common ≥1/100, ≤1/10</th>
<th>Uncommon ≥1/1,000, ≤1/100</th>
<th>Rare ≥1/10,000, ≤1/1,000</th>
<th>Very rare ≤1/10,000</th>
<th>Not known (cannot be estimated from the available data)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood and lymphatic system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thrombocytopenia</td>
<td></td>
</tr>
<tr>
<td>Nervous system disorders</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Paraesthesia, dysesthesia, hypoesthesia, peripheral neuropathy – also known to be associated with hypolipidaemic disorders</td>
<td></td>
</tr>
<tr>
<td>Gastrointestinal disorders</td>
<td>Headache, dizziness</td>
<td></td>
<td></td>
<td></td>
<td>Memory loss</td>
<td></td>
</tr>
<tr>
<td>Respiratory, thoracic and mediastinal disorders</td>
<td>Dyspepsia, abdominal pain, nausea, constipation, flatulence, diarrhoea</td>
<td></td>
<td></td>
<td>Acute pancreatitis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Skin and subcutaneous tissue disorders</td>
<td>Hypersensitivity reactions such as rash, urticaria.</td>
<td></td>
<td></td>
<td>Other skin reactions (e.g. eczema, dermatitis, bullous exanthema), face oedema, angioedema</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Exceptional cases of interstitial lung disease, especially with long term therapy (see section 4.4)
| Musculoskeletal and connective tissue disorders | Myalgia, muscle weakness, myopathy, muscle tenderness | Rhabdomyolysis, myositis, lupus erythematosus-like reactions |
| Vascular disorders | | Vasculitis |
| General disorders and administration site conditions | Fatigue | |
| Hepatobiliary disorders | | Hepatitis |
| Psychiatric disorders | Sleep disturbances, including insomnia and nightmares | Sexual dysfunction, depression |

**Laboratory Findings**
Confirmed elevations of transaminase levels to more than 3 times the upper limit of normal (ULN) developed in a small number of patients (less than or equal to 2%). Marked elevations of CK levels to more than 5 x ULN developed 0.3 - 1.0% of patients receiving licensed doses of fluvastatin in clinical trials.

4.9 **Overdose**
In a placebo-controlled study including 40 hypercholesterolaemic patients, doses up to 320 mg/day (n=7 per dose group) administered as fluvastatin 80mg XL tablets over two weeks were well tolerated. The experience with overdoses of fluvastatin 80mg XL tablets is very limited. Should an accidental overdosage occur, administration of activated charcoal is recommended. In the case of a very recent oral intake gastric lavage may be considered. Treatment should be symptomatic.

5 **PHARMACOLOGICAL PROPERTIES**

5.1 **Pharmacodynamic properties**
Pharmacotherapeutic group: HMG CoA reductase inhibitors
ATC code: C10AA04

Fluvastatin, a fully synthetic cholesterol-lowering agent, is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Vastacop XL exert its main effect in the liver. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The ultimate result of these mechanisms is a reduction of the plasma cholesterol concentration.

A variety of clinical studies have demonstrated that elevated levels of total cholesterol (total-C), LDL-C and apolipoprotein B (a membrane transport complex for LDL-C) promote human atherosclerosis. Similarly, decreased levels of high density lipoprotein cholesterol (HDL-C) and its transport complex, apolipoprotein A, are associated with the development of atherosclerosis. Epidemiologic investigations have established that cardiovascular morbidity and mortality vary directly with the level of total-C and LDL-C and inversely with the level of HDL-C. In multicentre clinical trials, those pharmacologic and/or non-pharmacologic interventions that simultaneously lowered LDL-C and increased HDL-C reduced the rate of cardiovascular events (both fatal and non-fatal myocardial infarctions). The overall cholesterol profile is improved with the principal effects being the reduction of total-C and LDL-C. Vastacop XL also produces a moderate reduction in triglycerides and a moderate increase in HDL-C. Therapeutic response is well established within 2 weeks, and maximum response is achieved within 4 weeks from treatment initiation and maintained during chronic therapy.
PAR Vastacop XL 80mg prolonged release tablets

UK/H/1108/01/DC

In the Vastacop XL Intervention Prevention Study (LIPS), the effect of fluvastatin on major adverse cardiac events (MACE) was assessed in patients with coronary heart disease who had first successful transcatheter therapy (TCT). The study included male and female patients (18-80 years old) and with baseline total cholesterol levels ranging from 3.5-7.0 mmol/L.

In this randomised, double-blind, placebo-controlled trial, a total of 1677 patients were recruited (844 in fluvastatin group and 833 in placebo group). The MACE was defined as cardiac death, non fatal MI and re-intervention (including CABG, repeat TCT, or TCT of a new lesion). The dose of fluvastatin used in this study was 80 mg daily over 4 years. Although the overall composite endpoint showed significant reduction in MACE (22%) compared to placebo (p=0.013), the individual components (cardiac death, non fatal MI and re-intervention) failed to reach statistical significance. There was however a trend in favour of fluvastatin. Therapy with fluvastatin reduced the risk of cardiac death and/or myocardial infarction by 31% (p=0.065).

5.2 Pharmacokinetic properties

Vastacop XL is a racemate of the two erythro enantiomers of which one exerts the pharmacological activity. Fluvastatin is absorbed rapidly and completely (98%) following oral administration to fasted volunteers. After oral administration of Vastacop XL and in comparison with the capsules, the absorption rate of fluvastatin is almost 60% slower while the mean residence time of fluvastatin is increased by approximately 4 hours. In a fed state, the drug is absorbed at a reduced rate. Fluvastatin exerts its main effect in the liver, which is also the main organ for its metabolism. The absolute bioavailability assessed from systemic blood concentrations is 24%. The apparent volume of distribution (Vd) for the drug is 330 L. More than 98% of the circulating drug is bound to plasma proteines, and this binding is unaffected by drug concentration.

The major circulating blood components are fluvastatin and the pharmacologically inactive N-desisopropyl-propionic acid metabolite. The hydroxylated metabolites have pharmacological activity but do not circulate systemically.

The hepatic metabolic pathways of fluvastatin in humans have been characterised. There are multiple, alternative cytochrome P450 (CYP450) pathways involved. However, the major pathway is mediated by CYP2C9 and this pathway is subject to potential interactions with other CYP2C9 substrates or inhibitors. In addition there are several minor pathways (e.g. CYP3A4).

Several detailed in vitro studies have addressed the inhibitory potential of fluvastatin on common CYP isoenzymes. Fluvastatin inhibited only the metabolism of compounds that are metabolised by CYP2C9.

Following administration of [3H]-fluvastatin to healthy volunteers, excretion of radioactivity is about 6% in the urine and 93% in the faeces, and fluvastatin accounts for less than 2% of the total radioactivity excreted. The plasma clearance (CL/f) for fluvastatin in man is calculated to be 1.8 ± 0.8 L/min.

Steady-state plasma concentrations show no evidence of fluvastatin accumulation following administration of 80 mg daily. Following oral administration of 40 mg of Fluvastatin the terminal disposition half-life for fluvastatin is 2.3 ± 0.9 hours.

Food - Mean AUC and Cmax were increased by 49% and 45% respectively and tmax prolonged when fluvastatin (fluvastatin 80mg XL tablets) was taken with food, compared to fasting state. However, no clinically obvious differences in the lipid-lowering effects and safety are anticipated when Vastacop XL is taken with or without food.

Plasma concentrations of fluvastatin do not vary as a function of age. Mean AUC and Cmax were increased by 36% and 44% respectively in females compared to males. However, no clinically obvious differences in the lipid lowering effects of fluvastatin are anticipated between males and females.

5.3 Preclinical safety data

Repeat toxicity studies with fluvastatin identified a variety of changes that are common to HMG-CoA reductase inhibitors, viz. hyperplasia and hyperkeratosis of the rodent non-glandular stomach, cataracts in dogs, myopathy in rodents, mild liver changes in most laboratory animals, with gall bladder changes in the dog, monkey and hamster, thyroid weight increases in the rat and testicular degeneration in the hamster. Fluvastin is devoid of the CNS vascular and degenerative changes recorded in dogs, myopathy in rodents, mild liver changes in most laboratory animals, with gall bladder changes in the dog, monkey and hamster, thyroid weight increases in the rat and testicular degeneration in the hamster. Fluvastin is devoid of the CNS vascular and degenerative changes recorded in dogs.

Carcinogenicity studies in rats and mice revealed a low incidence of forestomach squamous papillomas in mice and rats and one carcinoma in rats at the highest dose (18 mg/kg per day escalated to 24 mg/kg per day after 1 year). The forestomach neoplasms reflect chronic hyperplasia caused by direct contact exposure to fluvastatin rather than a genotoxic effect of the drug. In addition, an increased incidence of thyroid follicular cell neoplasms in male rats given the highest dose of fluvastatin was recorded. This is consistent with species-specific findings with other HMG-CoA reductase inhibitors. In contrast to other HMG-CoA reductase inhibitors, no treatment-related increases in the incidence of hepatic adenomas or carcinomas were observed.

In vitro and in vivo mutagenicity studies revealed no evidence of mutagenicity.
Reproductive toxicity studies indicated that fluvastatin had no adverse effects on fertility or reproductive performance in males or females, nor was it embryotoxic or teratogenic. Late gestational effects at high doses resulted in maternal mortality and fetal and neonatal lethality attributable to exaggerated pharmacological effects of fluvastatin during pregnancy.

6 PHARMACEUTICAL PARTICULARS

6.1 List of excipients

- Tablet core
  Carrageenan
  Magnesium stearate

- Film-coating
  Hydroxypropyl cellulose
  Hypromellose 6cP
  Iron oxide yellow
  Titanium dioxide
  Macrogol 8000
  Iron oxide red

6.2 Incompatibilities
Not applicable

6.3 Shelf life
24 months

6.4 Special precautions for storage
Do not store above 30°C. Store in the original package in order to protect from moisture.

6.5 Nature and contents of container
Alu/Alu blister consisting of an aluminium coating foil and an aluminium covering foil. Vastacop XL come in packs of 10, 14, 20, 28, 30, 49, 50, 96, 98, 100, 300 tablets. The pack of 300 tablets is intended for hospital use. And 28 and 98 tablets in date mark blister.
Not all pack sizes may be marketed

6.6 Special precautions for disposal
Any unused product or waste material should be disposed of in accordance with local requirements.

7 MARKETING AUTHORISATION HOLDER
Orifarm Generics A/S
Energivej 15
5260 Odense S
Denmark

8 MARKETING AUTHORISATION NUMBER(S)
PL 20254/0007

9 DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION
13/11/2008

10 DATE OF REVISION OF THE TEXT
13/11/2008
PACKAGE LEAFLET: INFORMATION FOR THE USER

Vastacop XL
80mg prolonged release tablets
Fluvastatin

Read all of this leaflet carefully before you start taking this medicine. Keep this leaflet. You may need to read it again. If you have any further questions, ask your doctor or pharmacist. This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:
1. What Vastacop XL is and what it is used for
2. Before you take Vastacop XL
3. How to take Vastacop XL
4. Possible side effects
5. How to store Vastacop XL
6. Further information

1. What Vastacop XL is and what it is used for

The active ingredient in your tablets is fluvastatin. This belongs to a group of medicines called statins and is used to help lower your blood cholesterol levels. This helps reduce the risk of shortening your life by reducing the risk of having a heart attack or stroke.

2. Before you take Vastacop XL

Do not take Vastacop XL:
- If you are allergic (hypersensitive) to fluvastatin or to any of the excipients of the medicine.
- If you are allergic to any of the ingredients of the tablets.
- If you have active liver problems or persistent raised liver blood test results.
- If you have any muscular disorders (affecting either yourself or other members of your family), previous muscular problems during treatment with other lipid-lowering medicines (e.g. other "statin" or "fibrate" medicines).
- If you are pregnant, or planning to become pregnant. If you do become pregnant whilst taking Vastacop XL tell your doctor.
- If you are breast-feeding.

Take special care with Vastacop XL:
- If you have a history of heavy alcohol consumption.
- If you have kidney problems.
- If you have underactive thyroid gland (hypothyroidism)
- If you have had a disease that may have affected your liver.
- If you develop problems whilst taking other medication that may affect your liver.
- If you have severe respiratory failure
- If you are less than 18 years of age.

Your doctor may need to carry out a blood test before and possibly during your Vastacop XL treatment. These blood tests will be used to predict your risk of muscle-related side effects. A blood test may also be required if you are older than 70 years in order to determine your risk of muscle-related side effects.

Using other medicines
Some medicines can interfere with your treatment or alter blood levels of those drugs you are currently taking, so make sure to check with your doctor or pharmacist before taking any other medications whether prescribed by a doctor or bought by you over the counter. In particular tell your doctor if you are taking any of the following:
- Ciclosporin (an immunosuppressive drug), the combination of Vastacop XL and ciclosporine may result in an increased risk of developing muscle problems.
- Drugs to prevent blood clotting (coumarin derivatives such as warfarin), the combination may lead to an increase in the effects of warfarin and cause bleeding.
- Other cholesterol lowering drugs such as fibric acid derivatives (e.g. gemfibrozil) or nicotinic acid, the combination may result in an increased risk of developing muscle problems.
- Erythromycin antibiotic, the combination may result in an increased risk of developing muscle problems.
- Rifampicin (antibacterial drug), the combination may result in a reduction in the effects of Vastacop XL.
- Phenylbutazone (anti-inflammatory medication), the combination may result in an increased amount of phenylbutazone in the blood which may cause side effects from the phenylbutazone. In addition the combination may result in increased blood levels of Vastacop XL which increases the risk of developing muscle problems.
- Vastacop XL is not usually prescribed with glibenclamide (antidiabetic drug). However, if your doctor thinks this is necessary you should be aware that the combination may result in an increase in amount of glibenclamide in the bloodstream, which may in turn lead to an increased risk of hypoglycaemia (low blood sugar).
- Itraconazole and fluconazole (antifungal drugs).
- Cimetidine and lansoprazole. These drugs may increase serum levels of fluvastatin.
- bile-acid sequestrating agents. Vastacop XL should be administered at least 4 hours after the resin (e.g. cholestyramine) to avoid a significant interaction due to drug binding to the resin.
- Colchicines. Concomitant administration of fluvastatin and colchicine may increase the possibility of myopathy.

Taking Vastacop XL with food and drink
- Vastacop XL can be taken at any time of day and be swallowed whole with a glass of water.
- Concomitant use of alcohol with fluvastatin should be avoided.

Pregnancy and Breast-feeding
- Do not take Vastacop XL if you are pregnant, planning to become pregnant, or breast-feeding. If you do become pregnant whilst taking Fluvastatin, tell your doctor.

Driving and using machines
Fluvastatin may cause dizziness and fatigue which could affect driving and using machines.
3. How to take Vastacop XL

You should always take your tablets exactly as advised by your doctor or pharmacist. You may have been started on a lower dose of fluvastatin. Vastacop XL 80mg should be taken once a day. This is the highest recommended dose per day of fluvastatin.

Do not chew

If you take more Vastacop XL than you should:
If you accidentally take too much of your medicine, tell your doctor immediately or go to your nearest casualty department.

If you forget to take Vastacop XL:
If you forget to take a dose, take one as soon as you remember, unless it is almost time for you to take your next dose. Then go on as before. Do not take a double dose to make up for a forgotten dose.

4. Possible Side Effects

Like all medicines, Vastacop XL can cause side effects, although not everybody gets them.

Serious side effects:
Serious side effects are rare (affecting less than 1 in 1000 patients) or very rare (affecting less than 1 in 10,000 patients).

The following are all serious side effects. You may need urgent medical attention if you have any of them.

- If you have unexplained muscle pain, tenderness or weakness, and particularly, if at the same time, you feel unwell or have fever. These might be early signs of a potentially severe muscle degradation which can be avoided if your doctor stops your treatment with fluvastatin as quickly as possible. These side effects have also been found with similar drugs of this class (statins).
- If you have unusual tiredness or fever, yellowing of the skin and eyes, dark coloured urine (signs of hepatitis).
- If you have signs of skin reactions such as skin rash, hives, redness, itching, swelling of the face, eyelids, and lips.
- If you bleed or bruise more easily than normal (signs of decreased number of platelets).
- If you have red or purple skin lesions (signs of blood vessel inflammation).
- If you have red blotchy rash mainly on the face which may be accompanied by fatigue, fever, joint pain, muscle pain (signs of lupus erythematosus-like reaction).
- If you have severe upper stomach pain (signs of inflamed pancreas).

If you experience any of these, tell your doctor straight away.

Other side effects:
Common (affecting less than 1 in 10 patients):
Difficulty in sleeping including insomnia and nightmares, headache, fatigue, dizziness, stomach discomfort, abdominal pain, constipation, flatulence, diarrhoea, nausea, joint pain.

Very rare (affecting less than 1 in 10,000 patients): Tingling or numbness of the hands or feet, disturbed or decreased sensations.

Not known, Breathing problems including persistent cough and/or shortness of breath or fever, memory loss, sexual difficulties.

If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

5. How to store Vastacop XL:

Do not store above 30°C.
Store in the original package in order to protect from moisture.

6. Further Information

What Vastacop XL contains:
The active substance is: fluvastatin. Each tablet contains 80 mg of fluvastatin as fluvastatin sodium.
The other ingredients are:
Tablet core: Carrageenan, Magnesium stearate
Film-coating: Hydroxypropyl cellulose, Hypromellose 60CP, Iron oxide yellow, Titanium dioxide, Macrogol 6000, Iron oxide red

What Vastacop XL looks like and contents of the pack
Vastacop XL are dark yellow, round, biconvex tablets and are packed in Aluminium/Aluminium blisters strips.
Each pack of Vastacop XL contains 18 or 14 or 29 or 28 or 30 or 49 or 50 or 96 or 98 or 100 or 300 tablets or 28 or 98 tablets in date mark blister.
Not all pack sizes may be marketed.

Marketing Authorisation Holder and Manufacturer
Omontis Generics A/S
Energavej 15, 5260 Odense S
Denmark

This leaflet was last approved in...MM/YYYY
Module 5

Scientific discussion during initial procedure

I  INTRODUCTION

Based on the review of the data on quality, safety and efficacy, the RMS considers that the application for Vastacop XL 80mg prolonged release tablets, in the indications:

- as an adjunct to diet for the reduction of elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL-C) levels, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate in patients with primary hypercholesterolaemia and mixed dyslipidaemia (Fredrickson Types IIa and IIb).

- in patients with coronary heart disease for the secondary prevention of coronary events after percutaneous coronary intervention

is approvable.

The application for Vastacop XL 80mg prolonged release tablets is abridged application made according to Article 10(1) of Directive 2001/83/EC submitted within the Decentralised Procedure with the UK acting as the Reference Member State (RMS). The Concerned Member States (CMS) are DE, FI, NO and SE. The reference medicinal product refers to Lescol 80mg prolonged release tablets, Novartis Pharmaceuticals Ltd (PL 00101/0587).

Fluvastatin, a fully synthetic cholesterol-lowering agent, is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The ultimate result of these mechanisms is a reduction of the plasma cholesterol concentration.

Fluvastatin is a racemate of the two erythro enantiomers of which one exerts the pharmacological activity. Fluvastatin is absorbed rapidly and completely (98%) following oral administration to fasted volunteers.

After oral administration of the UK reference product, LESCOL XL 80, and in comparison with the capsules, the absorption rate of fluvastatin is almost 60% slower while the mean residence time of fluvastatin is increased by approximately 4 hours. In a fed state, the drug is absorbed at a reduced rate. Fluvastatin exerts its main effect in the liver, which is also the main organ for its metabolism. The absolute bioavailability assessed from systemic blood concentrations is 24%. The apparent volume of distribution (Vd) for the drug is 330 L. More than 98% of the circulating drug is bound to plasma proteins, and this binding is unaffected by drug concentration.

The major circulating blood components are fluvastatin and the pharmacologically inactive N-desisopropyl-propionic acid metabolite. The hydroxylated metabolites have pharmacological activity but do not circulate systemically.
The hepatic metabolic pathways of fluvastatin in humans have been characterised. There are multiple, alternative cytochrome P<sub>450</sub> (CYP<sub>450</sub>) pathways involved. However, the major pathway is mediated by CYP2C9 and this pathway is subject to potential interactions with other CYP2C9 substrates or inhibitors. In addition there are several minor pathways (e.g. CYP3A4).

The RMS has been assured that acceptable standards of GMP are in place at all sites responsible for the manufacture and assembly of this product.

Full studies reports including copies of ethical committee approval documentation, and statements regarding GCP compliance have been provided.
## II. ABOUT THE PRODUCT

<table>
<thead>
<tr>
<th>Name of the product in the Reference Member State</th>
<th>Vastacop XL 80mg prolonged release tablets</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name(s) of the active substance(s) (INN)</td>
<td>Fluvastatin sodium</td>
</tr>
<tr>
<td>Pharmacotherapeutic classification (ATC code)</td>
<td>HMG CoA reductase inhibitors (C10AA)</td>
</tr>
<tr>
<td>Pharmaceutical form and strength(s)</td>
<td>80mg prolonged release tablets</td>
</tr>
<tr>
<td>Reference numbers for the Mutual Recognition Procedure</td>
<td>UK/H/1108/01/DC</td>
</tr>
<tr>
<td>Reference Member State</td>
<td>United Kingdom</td>
</tr>
<tr>
<td>Member States Concerned</td>
<td>DE, FI, NO, and SE</td>
</tr>
<tr>
<td>Marketing Authorisation Number(s)</td>
<td>PL 20254/0007</td>
</tr>
<tr>
<td>Name and address of the authorisation holder</td>
<td>Orifarm Generics A/S, Energivej 15, Odense S, DK-5260, Denmark</td>
</tr>
</tbody>
</table>
III SCIENTIFIC OVERVIEW AND DISCUSSION

QUALITY ASPECTS

Drug Substance

Nomenclature and structure

INN: Fluvastatin sodium

Chemical name(s):
6-Heptanoic acid, 7-(3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl)-3,5-dihydroxy-, monosodium salt, (R*,S*-(E))-(±)
Sodium (±)-(3R*,5S*,6E)-7-[3-(p-fluorophenyl)-1-isopropylindol-2-yl]-3,5-dihydroxy-6-heptanoate

CAS registry no.: 93957-55-2

Structural formula

\[
\begin{align*}
\text{Molecular formula} & : \quad C_{24}H_{25}FNNaO_4 \\
\text{Molecular weight (monosodium)} & : \quad 433.46
\end{align*}
\]

The drug substance is a white to pale-yellow, brownish–pale yellow or reddish–pale yellow, hygroscopic powder. It is optically active, as it holds 2 chiral centres:

Fluvastatin sodium is soluble in water, ethanol and methanol. A 1% w/v aqueous solution across three batches ranged in pH from 9.26 to 9.78.

This is subject to DMF. A letter of access has been provided.

Synthesis of the drug substance from the designated starting material has been adequately described and appropriate in-process controls and intermediate specifications are applied. Satisfactory specifications are in place for all starting materials and reagents and these are supported by relevant certificates of analysis.

Analytical methods have been appropriately validated and are satisfactory for ensuring compliance with the relevant specifications.
Fluvastatin sodium is stored in appropriate packaging. The specifications and typical analytical test reports are provided and are satisfactory.

Batch analysis data are provided and comply with the proposed specification.

Satisfactory certificates of analysis have been provided for working standards used by the active substance manufacturer and finished product manufacturer during validation studies.

Stability studies have been provided covering 18 months at 2-8°C and 18 months at 25°C/60% RH. A re-test period of 24 months when stored at 2°C-8°C is supported by the stability data presented.

**DRUG PRODUCT**

**Other ingredients**
Other ingredients consist of pharmaceutical excipients, namely ethanol absolute, magnesium stearate, Opadry 20F32403 Yellow, Gelcarin GP-379, Viscarin GP-209 and Water purified. All excipients used comply with their respective European Pharmacopoeia monograph with the exception of Gelcarin GP-379 and Viscarin GP-209 which comply with US pharmacopoeia and Opadry 20F32403 Yellow complies with in house specification.

Satisfactory certificates of analysis have been provided for all excipients.

Confirmation has been given that the magnesium stearate used in the tablets is of vegetable origin.

**Pharmaceutical development**
The objective of the pharmaceutical development programme was to produce Vastacop XL prolonged release tablets that could be considered as generic product to the originator product Lescol XL prolonged release tablets.

The rationale for the type of pharmaceutical form developed and formulation variables evaluated during development have been stated and are satisfactory.

**Dissolution and impurity profiles**
Dissolution and impurity profiles for the drug product were found to be similar to that for the reference product.

**Manufacture**
A description and flow-chart of the manufacturing method has been provided.

Satisfactory batch formulae have been provided for the manufacture of the product along with an appropriate account of the manufacturing process. The manufacturing process has been validated and appropriate in-process controls are applied.

**Finished product specification**
The finished product specification is satisfactory. Acceptance limits have been justified with respect to conventional pharmaceutical requirements and, where appropriate, safety. Test methods have been described and have been adequately validated, as appropriate. Batch data have been provided and comply with the release specification. Certificates of analysis have been provided for any working standards used.
Container Closure System
Product is packaged in to Aluminium blisters. Specifications and Certificates of Analysis for all packaging types used have been provided. These are satisfactory. All primary product packaging complies with EU legislation regarding contact with food.

Stability
Finished product stability studies have been conducted in accordance with current guidelines. Based on the results, a shelf-life of 2 years with storage conditions ‘protect from moisture’, store in the original package’ and ‘Do not store above 30 degree C’ are proposed. This is acceptable.

Bioequivalence/bioavailability
Satisfactory certificates of analysis have been provided for the test and reference batches used in the bioequivalence study. Bio-analytical methods used have been satisfactorily validated. Satisfactory bioequivalence is seen between the test and reference product.

SPC, PIL, Labels
The SPC, PIL and labels are pharmaceutically acceptable.

A package leaflet has been submitted to the MHRA along with results of consultations with target patient groups ("user testing"), in accordance with Article 59 of Council Directive 2001/83/EC. The results indicate that the package leaflet is well-structured and organised, easy to understand and written in a comprehensive manner. The test shows that the patients/users are able to act upon the information that it contains.

Conclusion
The proposed product has been shown to be a generic product of the reference product and has met the requirements with respect to qualitative and quantitative content of the active substance, pharmaceutical form and bioequivalence. Similar dissolution profiles have been demonstrated for the proposed and reference products. It is recommended that Marketing Authorisation should be granted for this application.
PRE-CLINICAL ASPECTS

No new preclinical data have been supplied with this application and none are required for an application of this type.
**CLINICAL ASPECTS**

1. **INTRODUCTION**
   This application is for Vastacop XL 80mg prolonged release tablets (PL 20254/0007) using the decentralised procedure. This is submitted on the basis of Directive 2001/83/EC Article 10(1) generic application. The applicant considers this product as generic medicinal product of Lescol XL 80mg prolonged release tablets that was authorised in the UK in 2000 (PL: 00101/0587).

2. **BACKGROUND**
   Fluvastatin, a fully synthetic cholesterol-lowering agent, is a competitive inhibitor of HMG-CoA reductase, which is responsible for the conversion of HMG-CoA to mevalonate, a precursor of sterols, including cholesterol. Vastacop XL exert its main effect in the liver. The inhibition of cholesterol biosynthesis reduces the cholesterol in hepatic cells, which stimulates the synthesis of LDL receptors and thereby increases the uptake of LDL particles. The ultimate result of these mechanisms is a reduction of the plasma cholesterol concentration.

3. **INDICATIONS**
   The applicant has submitted the following:
   
   Vastacop XL is indicated as an adjunct to diet for the reduction of elevated total cholesterol (total-C) and low-density lipoprotein cholesterol (LDL-C) levels, when response to diet and other non-pharmacological treatments (e.g. exercise, weight reduction) is inadequate in patients with primary hypercholesterolaemia and mixed dyslipidaemia (Fredrickson Types IIa and IIb).
   
   Vastacop XL is also indicated in patients with coronary heart disease for the secondary prevention of coronary events after percutaneous coronary intervention, see Section 5.1.

4. **DOSE & DOSE SCHEDULE**
   See the SPC for full details. The recommended dosages and dose schedules are consistent with the reference product.

5. **CLINICAL PHARMACOLOGY**

   **Pharmacokinetics**
   A standard open, randomized, crossover, single dose two-period bioequivalence study was designed. Fluvastatin 80mg prolonged release tablets (Pharmathen) were compared with Lescol XL 80mg tablets (Novartis Pharma AG, Swizerland) in healthy male individuals dosed after a high-fat breakfast. A washout period of seven days separated the two dosing days. Blood samples were collected before dosing and at 17 timed period after each dose. Eighty-five male volunteers were screened and enrolled for the project in accordance with the protocol requirements. They ranged in age from 18 to 55 years. Eighty-one of this number completed dosing with both formulations and were included in the kinetic analysis.
Table 1: Comparison of results across studies

<table>
<thead>
<tr>
<th>PK</th>
<th>Fed study (Study 3)</th>
<th>Fed study (Study 4)</th>
<th>Fasting study (Study 2)</th>
<th>Steady state (Study 1)</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUCt</td>
<td>1115.5, 1282.0 (83.23-96.06%)</td>
<td>588.3, 597.3 (96.99-108.75%)</td>
<td>283.0, 271.5 (99.38-115.45%)</td>
<td>AUC0-24 330.1, 328.8 (93.6-110.1%)</td>
</tr>
<tr>
<td>Cmax</td>
<td>469.0, 396.5 (108.29-140.93%)</td>
<td>197.8, 206.8 (90.31-108.48%)</td>
<td>72.7, 62.5 (107.08-124.74%)</td>
<td>74.00, 70.1 (96.29-113.63%)</td>
</tr>
<tr>
<td>Tmax*</td>
<td>5.00, 4.50</td>
<td>3.00, 3.00</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*median

There is a large disparity between the 2 fed studies. It was decided to repeat the fed study in view of the apparent disparity in values recorded. This is referred to as Study 4.

The applicant has clarified the reasons behind the disparity in results of the two fed studies.

It is considered that the improvements made in the chromatography for study, to improve the resolution of the fluvastatin peak and to ensure no interference, including from metabolites, is a satisfactory explanation for repeating the study.

Comparison of study 4- fed, and study 2-fasting, indicates the presence of a food effect where AUCt is increased by a factor of ~2.2 (for both test and reference) and Cmax increased by a factor of 2.7 (test) to 3.3 (reference). It is reassuring that both test and reference are increased in the same direction and to the same degree under these trial conditions. The rationale for leaving the product information reflecting the reference product is acceptable, given that bioequivalence has been demonstrated between test and reference products, and inter study comparisons between fed studies in this application and fed studies carried out by the reference product are difficult, given a different protocol and different meal composition.

Acceptable clarifications have been provided regarding subject disposition.

The 90% confidence interval ratio of geometric means for Cmin was 71.15 to 99.55 in the steady state study. Plasma values of Fluvastatin were either at zero or close to zero at 24 hours post dosing in 12% of Cmin values (14 observations in 118). Exclusion of subjects with any zero Cmin values, may have biased the Cmin analysis against the test product given that fewer subjects were excluded on the basis of 0 test values than for the reference. This also indicates that very low Cmin plasma levels occur not infrequently with the reference product. Given that this was foreseen prior to study, the justification for pre-specifying the Cmin variable as a secondary variable in this case, is considered acceptable.

**Pharmacokinetic conclusion**
Bioequivalence is considered to have been demonstrated between test and reference products.

**Pharmacodynamics**
No new data submitted or required.

6. **Efficacy**
No new clinical studies have been provided. The clinical overview provides a succinct
summary of the clinical efficacy.

7. SAFETY
No new clinical studies have been provided. The clinical overview provides a succinct summary of the clinical safety.

Pharmacovigilance system
The RMS considers that the Pharmacovigilance system as described by the applicant fulfils the requirements and provides adequate evidence that the applicant has the services of a qualified person responsible for pharmacovigilance and has the necessary means for the notification of any adverse reaction suspected of occurring either in the Community or in a third country.

Risk Management Plan
Only routine pharmacovigilance activities are proposed for the applicant’s post-authorisation safety monitoring of this product. This is considered acceptable.
Module 6

STEPS TAKEN AFTER INITIAL PROCEDURE - SUMMARY

<table>
<thead>
<tr>
<th>Date submitted</th>
<th>Application type</th>
<th>Scope</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>